Results 21 to 30 of about 2,541 (192)

Population pharmacodynamic modeling of eflornithine-based treatments against late-stage gambiense human African trypanosomiasis and efficacy predictions of l-eflornithine-based therapy [PDF]

, 2022
Eflornithine is a recommended treatment against late-stage gambiense human African trypanosomiasis, a neglected tropical disease. Standard dosing of eflornithine consists of repeated intravenous infusions of a racemic mixture of L- and D-eflornithine ...
Jansson Löfmark, Rasmus,, Amilon, Carl,, Tarning, Joel, Ashton, Michael,, Äbelö, Angela,, Boberg, Mikael,, Joel Tarning, Rasmus Jansson-Löfmark, Angela Äbelö, Carl Amilon, Mikael Boberg, Michael Ashton   +11 more
core   +1 more source

Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome

EMBO Molecular Medicine, 2023
Snyder–Robinson syndrome (SRS) results from mutations in spermine synthase (SMS), which converts the polyamine spermidine into spermine. Affecting primarily males, common manifestations of SRS include intellectual disability, osteoporosis, hypotonia, and
Tracy Murray Stewart, Jackson R Foley, Cassandra E Holbert, Maxim Khomutov, Noushin Rastkari, Xianzun Tao, Alex R Khomutov, R Grace Zhai, Robert A Casero   +8 more
doaj   +1 more source

Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease

eLife, 2021
Background: Polyamine levels are intricately controlled by biosynthetic, catabolic enzymes and antizymes. The complexity suggests that minute alterations in levels lead to profound abnormalities.
Surender Rajasekaran, Caleb P Bupp, Mara Leimanis-Laurens, Ankit Shukla, Christopher Russell, Joseph Junewick, Emily Gleason, Elizabeth A VanSickle, Yvonne Edgerly, Bryan M Wittmann, Jeremy W Prokop, André S Bachmann   +11 more
doaj   +1 more source

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study

PLoS Neglected Tropical Diseases, 2021
Background Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage gambiense human African trypanosomiasis (HAT) was added to the World Health Organization’s Essential Medicines List in 2009 after demonstration of its non ...
Andrea Kuemmerle, Caecilia Schmid, Sonja Bernhard, Victor Kande, Wilfried Mutombo, Medard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Ngolo Tete, Mays Kisala, Christian Burri, Severine Blesson, Olaf Valverde Mordt   +13 more
doaj   +2 more sources

Repurposing With Purpose: Treatment of Bachmann-Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies. [PDF]

Am J Med Genet C Semin Med Genet
ABSTRACT Rare diseases impact approximately 1 in 10 people worldwide, and yet, less than 5% of all rare diseases currently have an approved treatment option available. This is due to many challenges unique to rare diseases, including small, diverse patient populations, the cost of drug development that is not proportionate to the number of patients who
Bupp CP, VanSickle EA, Michael J, Schultz CR, Nguyen K, Hoefer M, Rajasekaran S, Bachmann AS.   +7 more
europepmc   +2 more sources

Systematic Review and Meta-Analysis on Human African Trypanocide Resistance

Pathogens, 2022
Background Human African trypanocide resistance (HATr) is a challenge for the eradication of Human African Trypansomiaisis (HAT) following the widespread emergence of increased monotherapy drug treatment failures against Trypanosoma brucei gambiense and ...
Keneth Iceland Kasozi, Ewan Thomas MacLeod, Susan Christina Welburn   +2 more
doaj   +1 more source

Characterisation and semi-mechanistic modelling of eflornithine pharmacokinetics and evalutation of prodrugs in oral treatment against late-stage human African trypanosomiasis [PDF]

, 2013
The present thesis explores the hypothesis that treatment of human African trypanosomiasis can be improved by characterising the enantioselective pharmacokinetics of eflornithine, and investigating the oral eflornithine absorption.
Johansson, Carl
core   +2 more sources

African Trypanosomiasis Research at a Crossroads: Bibliometric and Systematic Insights for the Future. [PDF]

J Parasitol Res
Aim Despite a reduction in the overall incidence and prevalence in the last two decades, trypanosomiasis continues to be a public health concern in Africa. This study was designed to comprehensively evaluate current trends in trypanosomiasis research using bibliometric approaches to uncover emerging topics and knowledge gaps, thereby guiding future ...
Ogra IO, Adaji JZ, Jonathan EU, Nwajiani BK, Usman S, Kurovsky A, Sossou K, Balogun EO.   +7 more
europepmc   +2 more sources

A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

Parasites & Vectors, 2018
Background While the combination of nifurtimox and eflornithine (NECT) is currently recommended for the treatment of the late stage human African trypansomiasis (HAT), single-agent eflornithine was still the treatment of choice when this trial commenced.
Freddie Kansiime, Seraphine Adibaku, Charles Wamboga, Franklin Idi, Charles Drago Kato, Lawrence Yamuah, Michel Vaillant, Deborah Kioy, Piero Olliaro, Enock Matovu   +9 more
doaj   +1 more source

Heteroleptic Transition Metal Complexes of Eflornithine Hydrochloride Monohydrate: Synthesis, Characterization, in silico and in vitro Biological Studies

Journal of the Turkish Chemical Society, Section A: Chemistry, 2022
Incessant development of resistance to drugs by microorganisms remains a major setback associated with the currently available antibiotics, thereby making imperative a continuous search for alternative candidates with improved efficacy.
Yusuf AYİPO
doaj   +1 more source